Dear Reader, 

THIS is the #1 stock to BUY for 2026.

It’s a bold new recommendation from one of the boldest men to ever rule Wall Street.

And for a limited time, he’s sharing this new recommendation live on-camera, completely free of charge.

His award-winning stock-rating system has pinpointed 8 of the top 10 stocks of the year every year for nearly a decade. (An 80% hit rate.)

His last recommendations shot up 100% and 160%.

And now he says this single ticker (not NVDA, TSLA, or any of the Mag 7) could double your money or MORE in the next 12 months.

It’s all part of his shocking new market prediction for 2026.

I just sat down with him and got all the details, along with his top stock for the year ahead.

To hear it for yourself 100% free, click here.

Regards,

Kelly Brown
Host, Chaikin Analytics

---

This Week’s Bonus Article

2 Healthcare Names That Could Get a Big Boost From Earnings

Submitted by Nathan Reiff. Article Published: 1/20/2026. 

Quick Look

• An acceleration from last quarter’s 4% year-over-year growth in nutrition segment sales could help boost Abbott Laboratories’ revenue performance.
• Intuitive Surgical’s preliminary fourth-quarter earnings results led to a modest dip in share price, perhaps due to middling forecasted da Vinci procedure growth for 2026.
• Still, overall adoption and revenue growth rates remain high, and the temporary decline may be an opportunity for long-term investors.

Active traders often see healthcare companies as candidates for sharp share-price moves tied to milestones in drug and device development. The sector can be volatile — high risk but potentially high reward. Another major catalyst is quarterly earnings. The two companies below could see meaningful upside (or downside) depending on the signals their earnings reports send when released in late January.

Analysts Expect Abbott to Overcome Nutrition Sluggishness

Abbott Laboratories (NYSE: ABT), a roughly $211 billion healthcare company that offers diagnostics, medical devices, pharmaceuticals and nutrition products, is best known for its continuous glucose monitoring (CGM) systems and cardiac and vascular devices.

$1,000 into $556,454. Impossible? (Ad)

Everyone knows NVIDIA is #1.

Some are shocked to learn Monster Energy is #2.

But #3? Nobody’s ever heard of it.

Even though it’s averaged 29% returns every year since 2000… enough to turn $1,000 into $556,454.

It doesn’t trade like a tech stock. And it was started as a private “trust fund” for the financial elite.Click here to discover why it’s so insanely profitable… and how anyone can access “The 29% Account

Abbott’s shares have been relatively flat over the past 12 months, returning about 4.3% and lagging the S&P 500.

In the third quarter of 2025, Abbott delivered EPS of $1.30, in line with expectations, but missed revenue estimates by more than $31 million despite roughly 7% year-over-year sales growth.

Weakness in the nutrition segment — sales there rose only about 4% YOY — was a key drag on revenue. Diagnostics in China also underperformed amid tariff and trade pressures. Still, those headline figures masked some bright spots, including a 17% YOY increase in CGM sales to about $2 billion.

Investors will be watching whether new higher-protein, lower-sugar versions of Ensure and Glucerna can reignite growth in the nutrition category. Those product launches could provide a meaningful lift to the segment and the company’s overall sales.

Given prior issues with volume-based procurement programs in China, Abbott may not have fully resolved the diagnostics headwinds there. That could be less significant if the company continues to perform well in medical devices, pharmaceuticals and its core lab diagnostics business outside China.

Wall Street appears optimistic heading into Abbott’s end-of-year earnings. Analysts at Barclays, Evercore ISI and others have reiterated Buy ratings or raised price targets recently. Consensus sees roughly 21% upside for ABT, with 19 analysts rating the stock a Buy versus four Holds.

Intuitive’s Preliminary Earnings Dip Could Be a Hidden Opportunity

Intuitive Surgical (NASDAQ: ISRG) is a major player focused on robot-assisted surgical systems. Preliminary results issued on Jan. 14, 2026 gave investors an early look at the company’s fourth-quarter performance: total worldwide procedures rose about 18% YOY, reflecting an aging population and growing demand for minimally invasive surgery.

Revenue for the quarter grew about 19% YOY to $2.87 billion, driven by continued adoption of the da Vinci system. Despite those strong metrics, the market reacted with a modest sell-off following the update.

One likely reason: the company’s 2026 procedure-growth guidance calls for da Vinci procedures to rise 13%–15%, slower than 2025’s 18% gain. That more conservative guidance probably disappointed some investors.

Still, Intuitive’s longer-term outlook remains compelling, supported by sustained demand for its systems and a pipeline that includes imaging agents and other therapeutics that are often overlooked.

If Intuitive’s official fourth-quarter report provides a fuller picture of its momentum and pipeline, the stock could rebound from the preliminary-driven dip. Analysts remain largely bullish: 18 rate ISRG a Buy versus nine combined Sell/Hold ratings, with consensus upside of more than 16%.

Thank you for subscribing to Earnings360, a morning newsletter that summarizes quarterly earnings for public companies that trade on U.S. markets.

This email is a paid sponsorship for Chaikin Analytics, a third-party advertiser of Earnings360 and MarketBeat. 

This ad is sent on behalf of Chaikin Analytics, 201 King Of Prussia Rd., Suite 650, Radnor, PA 19087. If you would like to optout from receiving offers from Chaikin Analytics please click here.


If you need assistance with your account, please don’t hesitate to email our South Dakota based support team at contact@marketbeat.com.

If you no longer wish to receive email from Earnings360, you can unsubscribe.

Copyright 2006-2026 MarketBeat Media, LLC. All rights protected.
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. USA..

Featured Link: 8,200% in 5 months. Their next pick could top it.(From Crypto 101 Media)